Search Results - "Giorgi, Ugo"

Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer by Sternberg, Cora N, Fizazi, Karim, Saad, Fred, Shore, Neal D, De Giorgi, Ugo, Penson, David F, Ferreira, Ubirajara, Efstathiou, Eleni, Madziarska, Katarzyna, Kolinsky, Michael P, Cubero, Daniel I. G, Noerby, Bettina, Zohren, Fabian, Lin, Xun, Modelska, Katharina, Sugg, Jennifer, Steinberg, Joyce, Hussain, Maha

“…Among men with high-risk, nonmetastatic, castration-resistant prostate cancer, the addition of enzalutamide to androgen-deprivation therapy improved overall…”
Get full text

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma by Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

“…Lenvatinib plus either pembrolizumab or everolimus was compared with sunitinib as first-line therapy for advanced renal cell cancer. Progression-free survival…”
Get full text

Bevacizumab As Maintenance Treatment in Patients With Ovarian Cancer: Wait for BRCA Testing by Farolfi, Alberto, Lorusso, Domenica, Pignata, Sandro, De Giorgi, Ugo

Get full text

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma by Motzer, Robert J, Hutson, Thomas E, Cella, David, Reeves, James, Hawkins, Robert, Guo, Jun, Nathan, Paul, Staehler, Michael, de Souza, Paul, Merchan, Jaime R, Boleti, Ekaterini, Fife, Kate, Jin, Jie, Jones, Robert, Uemura, Hirotsugu, De Giorgi, Ugo, Harmenberg, Ulrika, Wang, Jinwan, Sternberg, Cora N, Deen, Keith, McCann, Lauren, Hackshaw, Michelle D, Crescenzo, Rocco, Pandite, Lini N, Choueiri, Toni K

“…A number of agents are now approved for the treatment of renal cancer. A comparison of two agents, pazopanib and sunitinib, showed similar levels of antitumor…”
Get full text

The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer by Iacovelli, Roberto, Ciccarese, Chiara, Caffo, Orazio, De Giorgi, Ugo, Basso, Umberto, Tucci, Marcello, Mosillo, Claudia, Maruzzo, Marco, Maines, Francesca, Casadei, Chiara, Milella, Michele, Tortora, Giampaolo

“…Outcomes of castration-sensitive prostate cancer (CSPC) have improved owing to new therapies and early treatment, previously reserved for castration-resistant…”
Get full text

Statin use improves the efficacy of nivolumab in patients with advanced renal cell carcinoma by Santoni, Matteo, Massari, Francesco, Matrana, Marc R., Basso, Umberto, De Giorgi, Ugo, Aurilio, Gaetano, Buti, Sebastiano, Incorvaia, Lorena, Rizzo, Mimma, Martignetti, Angelo, Maslov, Diana, Tawagi, Karine, Philon, Ernest, Blake, Zoe, Porta, Camillo, Battelli, Nicola

“…Statins are widely used in an ageing population, including subjects with solid malignancies. However, no conclusive evidence is currently available on their…”
Get full text

The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives by Brighi, Nicole, Conteduca, Vincenza, Lolli, Cristian, Gurioli, Giorgia, Schepisi, Giuseppe, Palleschi, Michela, Mariotti, Marita, Casadei, Chiara, De Giorgi, Ugo

“…[Display omitted] •Treatment options for prostate cancer (PC) have greatly expanded in the last years.•Despite improvements in diagnosis and treatment options,…”
Get full text

Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group Registry by Cathomas, Richard, Klingbiel, Dirk, Bernard, Brandon, Lorch, Anja, Garcia Del Muro, Xavier, Morelli, Franco, De Giorgi, Ugo, Fedyanin, Mikhail, Oing, Christoph, Haugnes, Hege Sagstuen, Hentrich, Marcus, Fankhauser, Christian, Gillessen, Silke, Beyer, Jörg

“…Residual lesions after chemotherapy are frequent in metastatic seminoma. Watchful waiting is recommended for lesions < 3 cm as well as for fluorodeoxyglucose…”
Get full text

Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors by Casadei, Chiara, Dizman, Nazli, Schepisi, Giuseppe, Cursano, Maria Concetta, Basso, Umberto, Santini, Daniele, Pal, Sumanta K., De Giorgi, Ugo

“…Inhibitors of fibroblast growth factor receptor (FGFR) represent an outstanding treatment approach for selected patients with urothelial cancer (UC). These…”
Get full text

Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma by Mollica, Veronica, Santoni, Matteo, Matrana, Marc R., Basso, Umberto, De Giorgi, Ugo, Rizzo, Alessandro, Maruzzo, Marco, Marchetti, Andrea, Rosellini, Matteo, Bleve, Sara, Maslov, Diana, Tawagi, Karine, Philon, Ernest, Blake, Zoe, Massari, Francesco

“…Background Immune checkpoint inhibitors (ICIs) represent the standard of care as first- or second-line treatment in patients with renal cell carcinoma (RCC)…”
Get full text

Inflammatory indexes as predictors of prognosis and bevacizumab efficacy in patients with metastatic colorectal cancer by Passardi, Alessandro, Scarpi, Emanuela, Cavanna, Luigi, Dall'Agata, Monia, Tassinari, Davide, Leo, Silvana, Bernardini, Ilaria, Gelsomino, Fabio, Tamberi, Stefano, Brandes, Alba A, Tenti, Elena, Vespignani, Roberto, Frassineti, Giovanni L, Amadori, Dino, De Giorgi, Ugo

“…To investigate the role of pre-treatment inflammatory indexes (II) as predictors of prognosis and treatment efficacy in patients with metastatic colorectal…”
Get full text

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial by Motzer, Robert J, Dr Prof, Porta, Camillo, MD, Vogelzang, Nicholas J, Prof, Sternberg, Cora N, MD, Szczylik, Cezary, Prof, Zolnierek, Jakub, MD, Kollmannsberger, Christian, MD, Rha, Sun Young, MD, Bjarnason, Georg A, MD, Melichar, Bohuslav, Prof, De Giorgi, Ugo, MD, Grünwald, Viktor, Prof, Davis, Ian D, MBBS, Lee, Jae-Lyun, Prof, Esteban, Emilio, Prof, Urbanowitz, Gladys, MBA, Cai, Can, PhD, Squires, Matthew, PhD, Marker, Mahtab, PhD, Shi, Michael M, MD, Escudier, Bernard, Prof

“…Summary Background An unmet medical need exists for patients with metastatic renal cell carcinoma who have progressed on VEGF-targeted and mTOR-inhibitor…”
Get full text

Local treatment for oligoprogressive metastatic sites of breast cancer: efficacy, toxicities and future perspectives by Merloni, Filippo, Palleschi, Michela, Gianni, Caterina, Sirico, Marianna, Serra, Riccardo, Casadei, Chiara, Sarti, Samanta, Cecconetto, Lorenzo, Menna, Giandomenico Di, Mariotti, Marita, Maltoni, Roberta, Montanari, Daniela, Romeo, Antonino, Giorgi, Ugo De

“…Metastatic breast cancer (MBC) is still an incurable disease, which eventually develops resistance mechanisms against systemic therapies. While most patients…”
Get full text

Circulating AR copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer by Salvi, Samanta, Casadio, Valentina, Conteduca, Vincenza, Lolli, Cristian, Gurioli, Giorgia, Martignano, Filippo, Schepisi, Giuseppe, Testoni, Sara, Scarpi, Emanuela, Amadori, Dino, Calistri, Daniele, Attard, Gerhardt, De Giorgi, Ugo

“…In the present study, we aimed to evaluate the association of circulating AR copy number (CN) and outcome in a cohort of patients with advanced…”
Get full text

Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer by De Giorgi, Ugo, Mego, Michal, Scarpi, Emanuela, Giordano, Antonio, Giuliano, Mario, Valero, Vicente, Alvarez, Ricardo H., Ueno, Naoto T., Cristofanilli, Massimo, Reuben, James M.

“…Background: We retrospectively evaluated the correlation between a baseline measurement of circulating tumor cells (CTCs) and inflammation-based scores in…”
Get full text

Hyperphosphatemia Secondary to the Selective Fibroblast Growth Factor Receptor 1–3 Inhibitor Infigratinib (BGJ398) Is Associated with Antitumor Efficacy in Fibroblast Growth Factor Receptor 3–altered Advanced/Metastatic Urothelial Carcinoma by Lyou, Yung, Grivas, Petros, Rosenberg, Jonathan E., Hoffman-Censits, Jean, Quinn, David I., P. Petrylak, Daniel, Galsky, Matthew, Vaishampayan, Ulka, De Giorgi, Ugo, Gupta, Sumati, Burris, Howard, Rearden, Jessica, Li, Ai, Wang, Hao, Reyes, Maribel, Moran, Susan, Daneshmand, Siamak, Bajorin, Dean, Pal, Sumanta K.

“…Infigratinib (BGJ398) is a potent, selective fibroblast growth factor receptor (FGFR) 1–3 inhibitor with significant activity in metastatic urothelial…”
Get full text

Computed tomography based analyses of body mass composition in HER2 positive metastatic breast cancer patients undergoing first line treatment with pertuzumab and trastuzumab by Palleschi, Michela, Prochowski Iamurri, Andrea, Scarpi, Emanuela, Mariotti, Marita, Maltoni, Roberta, Mannozzi, Francesca, Barone, Domenico, Paganelli, Giovanni, Casi, Michela, Giampalma, Emanuela, De Giorgi, Ugo, Rocca, Andrea

“…Body composition parameters (BCp) have been associated with outcome in different tumor types. However, their prognostic value in patients with HER2-positive…”
Get full text

Treatment‐related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: An up‐to‐date review and meta‐analysis of clinical trials by Santoni, Matteo, Conti, Alessandro, Massari, Francesco, Arnaldi, Giorgio, Iacovelli, Roberto, Rizzo, Mimma, Giorgi, Ugo, Trementino, Laura, Procopio, Giuseppe, Tortora, Giampaolo, Cascinu, Stefano

“…Fatigue is the most common symptom associated with cancer and cancer treatment. We performed an up‐to‐date meta‐analysis to determine the incidence and…”
Get full text

KEYNOTE-991: pembrolizumab plus enzalutamide and androgen deprivation for metastatic hormone-sensitive prostate cancer by Gratzke, Christian, Kwiatkowski, Mariusz, De Giorgi, Ugo, Martins da Trindade, Karine, De Santis, Maria, Armstrong, Andrew J, Niu, Cuizhen, Liu, Yingjie, Poehlein, Christian Heinrich

“…Current treatment for patients with metastatic hormone-sensitive prostate cancer (mHSPC) delays disease progression and improves survival, but resistance is…”
Get full text

Spotlight on PSMA as a new theranostic biomarker for bladder cancer by Tumedei, Maria Maddalena, Ravaioli, Sara, Matteucci, Federica, Celli, Monica, De Giorgi, Ugo, Gunelli, Roberta, Puccetti, Maurizio, Paganelli, Giovanni, Bravaccini, Sara

“…Bladder cancer (BCa) patients are diagnosed by cytology and cystoscopy. However, these diagnostic tests bear some limitations. We sought for reliable…”
Get full text